Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks
Jul 5, 2015 ·
2m 57s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can...
show more
A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.
show less
Information
| Author | cancerGRACE |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
